Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

Core Insights - Elanco Animal Health celebrates the second annual National Parvo Awareness Day to raise awareness about canine parvovirus, a highly contagious and often fatal disease affecting puppies [1][9] - The Canine Parvovirus Monoclonal Antibody (CPMA) has received conditional approval from the USDA and has significantly improved survival rates for infected puppies, with a 93% survival rate reported [5][9] - Elanco aims to save 1 million puppies from parvovirus by 2030 and emphasizes the importance of making CPMA widely available, especially in resource-strained shelter environments [6][9] Company Initiatives - Elanco has launched ParvoTrack, a real-time online tool for tracking parvovirus outbreaks, allowing pet owners and veterinarians to self-report cases and receive alerts [6][9] - The company has reported thousands of parvo cases since the launch of ParvoTrack, with significant outbreaks noted in states like Texas, Arizona, and Florida [6][9] - Elanco is committed to increasing access to CPMA and encourages clinics and shelters to adopt this treatment to combat parvovirus effectively [6][7] Treatment Impact - Puppies treated with CPMA spend an average of 1.87 fewer days in the hospital, alleviating the emotional burden on veterinary staff and facilitating quicker reunions with families [5][9] - Real-world usage of CPMA has shown a 93% survival rate for parvo-infected puppies, marking a significant advancement in treatment options [5][9] - Testimonials from veterinarians highlight the positive change in attitudes towards parvovirus outbreaks since the introduction of CPMA, emphasizing its critical role in treatment [7][9]